| Literature DB >> 26163883 |
Sebastian Demkowicz1, Witold Kozak2, Mateusz Daśko2, Maciej Masłyk3, Bartłomiej Gielniewski3, Janusz Rachon2.
Abstract
Based on the frameworks of 7-hydroxy-2,3-dihydro-1H-cyclopenta[c]chromen-4-one, 3-hydroxy-7,8,9,10-tetrahydro-6H-benzo[c]chromen-6-one and 3-hydroxy-8,9,10,11-tetrahydro-7H-cyclohepta[c]chromen-6-one, a series of bicoumarin thiophosphate analogs have been synthesized and biologically evaluated. Additionally, their binding modes have been modeled using docking techniques. The inhibitory properties of the synthesized compounds were tested against the STS isolated from human placenta. Most of the new STS inhibitors possessed good activities against STS. In particular, we found that the bis-(6-oxo-7,8,9,10-tetrahydro-6H-benzo[c]chromen-3-yl) hydrogenthiophosphate (10b) produced the largest inhibitory effect, with an IC50 value of 860 nM (an IC50 value of 1 μM for the 665-COUMATE used as a reference). The structure-activity relationships of the synthesized bicoumarin thiophosphate derivatives toward the STS enzyme have been discussed previously.Entities:
Keywords: Bicoumarin thiophosphates; Breast cancer; Molecular docking; STS inhibitors; Steroid sulfatase
Mesh:
Substances:
Year: 2015 PMID: 26163883 DOI: 10.1016/j.ejmech.2015.06.051
Source DB: PubMed Journal: Eur J Med Chem ISSN: 0223-5234 Impact factor: 6.514